ShadowBuys

Lobbying disclosures · Lobbying report

AMGN: second_quarter 2026 lobbying report

Issues related to visas Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021

Follow AMGN
Became public
Jul 20, 2026, 11:17 AM EDT
Event / period date
Not stated
Collected
Nov 8, 2026, 11:40 AM EST

Why this is connected

Exact legal-name match: AMGEN INC (https://www.sec.gov/Archives/edgar/data/318154/).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/1ce4b9e9-92c8-4e50-8a27-ad73746318ca/","filing_uuid":"1ce4b9e9-92c8-4e50-8a27-ad73746318ca","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/1ce4b9e9-92c8-4e50-8a27-ad73746318ca/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey Miller","dt_posted":"2026-07-20T11:17:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"P.O. Box 625","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Buda","registrant_state":"TX","registrant_zip":"78610","registrant":{"id":401104313,"url":"https://lda.gov/api/v1/registrants/401104313/","house_registrant_id":null,"name":"MILLER STRATEGIES, LLC","description":"strategic public affairs","address_1":"P.O. Box 625","address_2":null,"address_3":null,"address_4":null,"city":"Buda","state":"TX","state_display":"Texas","zip":"78610","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JEFFREY MILLER","contact_telephone":"+1 202-434-8242","dt_updated":"2026-07-30T15:40:39.312430-04:00"},"client":{"id":201397,"url":"https://lda.gov/api/v1/clients/201397/","client_id":354,"name":"AMGEN, INC.","general_description":"biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-01-01"},"lobbying_activities":[{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"Issues related to visas","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in AMGN

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.